Laura Licchetta1, Tommaso Pippucci2, Sara Baldassari3, Raffaella Minardi4, Federica Provini5, Barbara Mostacci4, Giuseppe Plazzi5, Paolo Tinuper5, Francesca Bisulli5. 1. IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. Electronic address: laura.licchetta2@unibo.it. 2. Medical Genetics Unit, Polyclinic Sant'Orsola-Malpighi University Hospital, Bologna, Italy. 3. Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. 4. IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. 5. IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Abstract
PURPOSE: Genetics of Sleep-related Hypermotor Epilepsy (SHE) includes mutations in several genes that cumulatively account for 30 % of families. This approximate estimate comes from different case-series, each focused on the screening of a single gene. We systematically investigated a large cohort of SHE patients to estimate the frequency of pathogenic variants in the main genes thus far implicated in this epilepsy syndrome. METHODS: We selected familial and isolated cases diagnosed with clinical/confirmed SHE who underwent genetic analysis by comparable next generation sequencing (NGS) techniques (WES/ multigene epilepsy panel). The identified heterozygous variants were classified according to the American College of Medical Genetics and Genomics guidelines. RESULTS: We included 103 SHE patients (M/F:61/42) who underwent NGS. Sixteen (15.5 %) were familial cases, 16.5 % had focal cortical dysplasia (FCD). We identified three pathogenic variants in CHRNA4 (2.9 %, CI: 0.6-8.3 %), two of whom novel; one pathogenic variant in KCNT1 (1 %, CI: 0.02-5.29 %); four loss-of-function variants in DEPDC5 (3.9 %, CI: 1.1-9.7 %), one of whom never reported; finally, one missense change in NPRL2 (1 %, CI: 0.02-5.29 %), already reported as pathogenic. Three out of the four patients with DEPDC5 variants had FCD. CONCLUSIONS: The overall frequency of pathogenic variants in our SHE cohort was 8.7 %, 19 % and 7 % considering familial and sporadic cases, respectively. Pathogenic variants in the GATOR1-complex genes account for 5 % of the cases. DEPDC5 shows the highest variants frequency, especially in patients with genetic-structural etiology. From a practical perspective, analysis of this gene is recommended even in isolated cases, because of possible implications for patient management.
PURPOSE: Genetics of Sleep-related Hypermotor Epilepsy (SHE) includes mutations in several genes that cumulatively account for 30 % of families. This approximate estimate comes from different case-series, each focused on the screening of a single gene. We systematically investigated a large cohort of SHE patients to estimate the frequency of pathogenic variants in the main genes thus far implicated in this epilepsy syndrome. METHODS: We selected familial and isolated cases diagnosed with clinical/confirmed SHE who underwent genetic analysis by comparable next generation sequencing (NGS) techniques (WES/ multigene epilepsy panel). The identified heterozygous variants were classified according to the American College of Medical Genetics and Genomics guidelines. RESULTS: We included 103 SHE patients (M/F:61/42) who underwent NGS. Sixteen (15.5 %) were familial cases, 16.5 % had focal cortical dysplasia (FCD). We identified three pathogenic variants in CHRNA4 (2.9 %, CI: 0.6-8.3 %), two of whom novel; one pathogenic variant in KCNT1 (1 %, CI: 0.02-5.29 %); four loss-of-function variants in DEPDC5 (3.9 %, CI: 1.1-9.7 %), one of whom never reported; finally, one missense change in NPRL2 (1 %, CI: 0.02-5.29 %), already reported as pathogenic. Three out of the four patients with DEPDC5 variants had FCD. CONCLUSIONS: The overall frequency of pathogenic variants in our SHE cohort was 8.7 %, 19 % and 7 % considering familial and sporadic cases, respectively. Pathogenic variants in the GATOR1-complex genes account for 5 % of the cases. DEPDC5 shows the highest variants frequency, especially in patients with genetic-structural etiology. From a practical perspective, analysis of this gene is recommended even in isolated cases, because of possible implications for patient management.
Authors: Christina Cherian; Juan P Appendino; Setareh Ashtiani; Paolo Federico; Christine P Molnar; Marina Kerr; Aneal Khan; Ping Yee Billie Au; Karl Martin Klein Journal: J Neurol Date: 2021-09-19 Impact factor: 4.849
Authors: Christopher J Re; Alexander I Batterman; Jason R Gerstner; Russell J Buono; Thomas N Ferraro Journal: Front Neurol Date: 2020-06-23 Impact factor: 4.003
Authors: Carmen Arenas-Cabrera; Pablo Baena-Palomino; Javier Sánchez-García; María Oliver-Romero; Yamin Chocrón-González; Manuel Caballero-Martínez Journal: J Cent Nerv Syst Dis Date: 2022-02-11
Authors: Luca Gozzelino; Gaga Kochlamazashvili; Sara Baldassari; Albert Ian Mackintosh; Laura Licchetta; Emanuela Iovino; Yu Chi Liu; Caitlin A Bennett; Mark F Bennett; John A Damiano; Gábor Zsurka; Caterina Marconi; Tania Giangregorio; Pamela Magini; Marijn Kuijpers; Tanja Maritzen; Giuseppe Danilo Norata; Stéphanie Baulac; Laura Canafoglia; Marco Seri; Paolo Tinuper; Ingrid E Scheffer; Melanie Bahlo; Samuel F Berkovic; Michael S Hildebrand; Wolfram S Kunz; Lucio Giordano; Francesca Bisulli; Miriam Martini; Volker Haucke; Emilio Hirsch; Tommaso Pippucci Journal: Brain Date: 2022-07-29 Impact factor: 15.255
Authors: Anna Morgan; Flavio Faletra; Giulia Severi; Martina La Bianca; Laura Licchetta; Paolo Gasparini; Claudio Graziano; Giorgia Girotto Journal: Biomedicines Date: 2021-12-22